Tag Archives: durvalumab

November, 2018

September, 2018

July, 2018

May, 2018

September, 2017

  • 7 September

    FDA Places Clinical Hold on Celgene’s Fusion Clinical Program

    SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION™ program. The trials are testing IMFINZI™ (durvalumab), an anti-PD-L1 antibody, in combination with immunomodulatory and chemotherapy agents …

July, 2017

May, 2017